The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Psychedelics and the essential importance of context
Abstract
Psychedelic drugs are making waves as modern trials support their therapeutic potential and various media continue to pique public interest. In this opinion piece, we draw attention to a long-recognised component of the psychedelic treatment model, namely ‘set’ and ‘setting’ – subsumed here under the umbrella term ‘context’. We highlight: (a) the pharmacological mechanisms of classic psychedelics (5-HT2A receptor agonism and associated plasticity) that we believe render their effects exceptionally sensitive to context, (b) a study design for testing assumptions regarding positive interactions between psychedelics and context, and (c) new findings from our group regarding contextual determinants of the quality of a psychedelic experience and how acute experience predicts subsequent long-term mental health outcomes. We hope that this article can: (a) inform on good practice in psychedelic research, (b) provide a roadmap for optimising treatment models, and (c) help tackle unhelpful stigma still surrounding these compounds, while developing an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The psychedelic experience comes with an increased sensitivity to internal and external stimuli.”
In the citing paper
“It follows that the general context of psychedelic administration fundamentally shapes drug response and hence safety, as well as potentially therapeutic efficacy [9, 88].”
In the citing paper
“This highlights the frequent clinical observation that patients may need particularly intensive supportive care during, as well as after psychedelic experiences (Carhart-Harris et al., 2018).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Carhart-Harris et al., 2018
In the citing paper
“Psychedelic experiences vary depending not only on individual characteristics, such as health status, but also on the type of preparation available, intentions agreed upon before the experience, and the environment in which the experience takes place (Carhart-Harris et al., 2018; Golden et al., 2022).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Carhart-Harris et al., 2018
In the citing paper
“It has long been recognised that both set (the mindset of the participant, including their expectations, assumptions and intentions for the psychedelic experience, as well as stable variables such as personality and the presence of psychopathology) and setting (the physical, social and cultural environment in which the experience occurs) have the potential to greatly impact the outcomes of the Psy”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [43]
In the citing paper
“Contextual factors, such as the environment in which the experience takes place (setting), the mindset of the individual (set), and the support available after the experience (integration and setting), have a huge impact on the effects of psychedelics (85–88).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [85]
In the citing paper
“Differences in set and setting, which involve factors such as opportunity for preparation, guidance and integration by a trained guide, have been extensively shown to greatly influence the acute psychedelic experience (136, 137).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [136]
In the citing paper
“Changes in the ratings of subjective measures that were observed in the present study are not necessarily related to a pharmacological effect of 5-MeO-DMT, but could have resulted from uncontrolled variables such as response expectancy of the participants prior to and after the session or the set and setting of drug administration (Carhart-Harris et al. 2018; Hartogsohn 2016).”
From Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment (2020) · cites this paper as Carhart-Harris et al. 2018
Citations
Cites
Mediators and Mechanisms of Change in Psychotherapy Research
Kazdin, A. E. (2007) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.3.022806.091432 · Cited by 2,504 · cited 1×
“Therapeutic alliance is already known to be a major predictor of response in mental healthcare (Kazdin, 2007) and if the present thesis is correct, its influence is likely to be greater still in the context of psychedelics (see Carhart-Harris and Nutt, 2017).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 4×
“Indirect support for this may be found in the not inconsiderable (before-versus-after treatment) effects sizes observed in control conditions in recent double-blind randomised control trials of psilocybin for end-of-life distress, for example (Griffiths et al., 2016).”
BackgroundMethodInfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“In model 1, it can be seen that: (a) feeling ready to ‘surrender’ to the experience, (b) having a clear intention for it, (c) having the experience in a therapeutic setting, and (d) taking a higher dose, are all predictive of having a certain kind of psychedelic experience which we label ‘peak’ – an intentionally secu…”
BackgroundCaspi, A., Hariri, A. R., Holmes, A., Uher, R., & Moffitt, T. E. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09101452 · Cited by 1,346
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Religions, Values, and Peak-Experiences
Jones, R. G., & Maslow, A. H. (1965) · Journal for the Scientific Study of Religion · doi:10.2307/1384286 · Cited by 949
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Self-citation
Research works printed but not linked: 10
- Aixala M, 2017, Psychotherapeutic Intervention in Integration of Difficult Psychedelic Experiences: The ICEERS Support Service
- Albarelli HP, 2009, A Terrible Mistake: The Murder of Frank Olson and the CIA’s Secret Cold War Experiments
- Hartogsohn I, 2015, The Psycho-Social Construction of LSD: How Set and Setting Shaped the American Psychedelic Experience 1950–1970
- Hartogsohn I, 2017, Drug Sci Pol Law, 3, 1
- Hofmann A, 1980, LSD: My Problem Child
- Krebs TS, 2012, J Psychopharmacol, 26, 994
- Lee MA, 1992, Acid Dreams: The Complete Social History of LSD, the CIA, the Sixties and Beyond
- Schwartz C (2017) Molly at the Marriott: Inside America’s Premier Psychedelics conference. The New York Times. Available at: https://www.nytimes.com/2017/05/06/style/psychedelic-drug-resurgence-daily-life.html (accessed 6 May 2017).
- Sos P, 2013, Neuro Endocrinol Lett, 34, 287
- Waldman A, 2017, A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life
Cited by
Sorted by citations
Items 401–500 of 655
What are set and setting: Reducing vagueness to improve research and clinical practice
Patch, K., & Smith, W. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251337372 · Cited by 6
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5
Molumby, M., Gaynor, K., Guérin, S., & McNamara, R. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221110331 · Cited by 5
Bienemann, B., Barbosa, A. R., da Cruz, L. V. M., Multedo, M., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2226414 · Cited by 5
Davis, A. K., Timmermann, C., Bernal, A. M. O., Lancelotta, R., Nayak, S. M., Sepeda, N. D., Nikolaidis, A., & Griffiths, R. R. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2232379 · Cited by 5
Orlowski, P., Hobot, J., Ruban, A., Szczypiński, J., & Bola, M. (2024) · Psychophysiology · doi:10.1111/psyp.14583 · Cited by 5
Preferences and Attitudes Toward Music in Nonclinical Uses of Psychedelics
Gloeckler, S. G., Lehmann, A., de la Salle, S., Greenway, K. T., & Lucas, P. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0003 · Cited by 5
Carvour, H. M., Radke, A. K., & French, N. S. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1587794 · Cited by 9
Donegan, C. J., Daldegan‐Bueno, D., Noorani, T. N., Sumner, R. L., Forsyth, A., Evans, W., Smith, T., Hoeh, N. R., Sundram, F., Menkes, D. B., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110670 · Cited by 4
A causal pluralist theory of the interaction of substance, set and setting in psychedelic experience
Kiverstein, J. D., Beyköylü, H., & van Elk, M. (2025) · Philosophical Psychology · doi:10.1080/09515089.2025.2590741 · Cited by 4
Ostrand, A. E., Nour, M. M., Timmermann, C., Rosati, A., Luan, L., Gómez-Emilsson, A., Bornemann, J., Greenway, K. T., Roseman, L., & Carhart-Harris, R. L. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261464986 · Cited by 4
Self-citationSyed, O. A., Tsang, B., Nestor, S. M., Lipsman, N., Husain, M. I., Alam, F., & Giacobbe, P. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106573 · Cited by 5
Cherniak, A. D., Granqvist, P., Mikulincer, M., & Wolff, M. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2644857 · Cited by 4
In naturalistic psychedelic use, group use is common and acceptable
Byrne, K., Lindsay, S., Baker, N. J., Schmutz, C., & Lewis, B. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00261 · Cited by 5
Poggini, S., Bon, G. M., Albanese, N. C., Karpova, N. N., Ċastrén, E., D’Andrea, I., & Branchi, I. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.145 · Cited by 4
Self-citationFischman, L. G. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1469559 · Cited by 7
Exploring Motivations, Experiences, and Consequences of Psychedelic Use in Aotearoa New Zealand
Mills, E., Whelan, J., McGruddy, S., & Ward, R. D. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2474236 · Cited by 4
Bălăeţ, M., Trender, W. R., Lerede, A., Hellyer, P. J., & Hampshire, A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251346729 · Cited by 6
Jylkkä, J., Väyrynen, H., Lin, E., Walldén, C., Krabbe, A., Kähönen, J., & Sikka, P. (2025) · Consciousness and Cognition · doi:10.1016/j.concog.2025.103901 · Cited by 7
Harm reduction practises for users of psychedelic drugs: a scoping review
Dutton, C., North, E., Tie, Y. C., Oliva, J., & Skeffington, P. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01264-2 · Cited by 6
Carl Jung and the Psychedelic Brain
Clark, G. (2021) · International Journal of Jungian Studies · doi:10.1163/19409060-bja10017 · Cited by 5
L’émergence des psychothérapies assistées au LSD (1950-1970)
Dubus, Z. (2022) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2022.11.002 · Cited by 4
Lawrence, D. W., Battista, A. P. D., & Timmermann, C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2230568 · Cited by 4
Brouwer, A., Raison, C. L., & Shults, F. L. (2024) · Religion Brain & Behavior · doi:10.1080/2153599x.2024.2349151 · Cited by 5
Swanson, L. R., Jungers, S., Varghese, R., Cullen, K. R., Evans, M. D., Nielson, J. L., & Schallmo, M. (2024) · Journal of Vision · doi:10.1167/jov.24.12.5 · Cited by 6
Henry, J. S., Giribaldi, B., Nutt, D. J., Erritzøe, D., Carhart-Harris, R. L., & Lyons, T. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.06.003 · Cited by 5
Self-citationVohryzek, J., Luppi, A. I., Atasoy, S., Deco, G., Carhart-Harris, R. L., Timmermann, C., & Kringelbach, M. L. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02190-4 · Cited by 12
Self-citationEthische Aspekte der Therapie mit Psychedelika
Repantis, D., Koslowski, M., & Fink, S. B. (2024) · Die Psychotherapie · doi:10.1007/s00278-024-00710-z · Cited by 5
Psychedelic therapies and belief change: are there risks of epistemic harm or epistemic injustice?
Zeller, M. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2362284 · Cited by 4
Prochazkova, L., van Elk, M., Marschall, J., Rifkin, B. D., Fejer, G., Schon, N. R., Fiacchino, D., Kuchař, M., & Hommel, B. (2021) · doi:10.31234/osf.io/emcxw · Cited by 4
Natural Language as a Window into the Subjective Effects and Neurochemistry of Psychedelic DrugsPreprint
Tagliazucchi, E. (2021) · Preprints.org · doi:10.20944/preprints202111.0201.v1 · Cited by 3
Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI
Kargbo, R. B. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00333 · Cited by 4
Adamczyk, S., Paczyńska, M., Ruban, A., Szczypiński, J., Bola, M., & Orlowski, P. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2464797 · Cited by 5
Modlin, N. L., Williamson, V., Maggio, C., Stubley, J., Kirlić, N., Cleare, A. J., & Rucker, J. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251342319 · Cited by 3
Understanding the Experience of Ketamine-Assisted Therapy and the Importance of Context
Stockwell, G., Hoeh, N. R., Fogarty, F. A., Clayden, C., & Reynolds, L. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2527299 · Cited by 3
McGovern, H. T., Bajo, L., Hassed, G., Hoefnagels, R., Levey, M., Rose, N., Foe, A. D., & Hutchinson, B. T. (2025) · Brain and Behavior · doi:10.1002/brb3.70687 · Cited by 4
Suggestion Effects in Psychedelics: Confounds and Opportunities
Stein, M. V., & Terhune, D. B. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2501964 · Cited by 6
Gezon, L. L., & Bartlett, K. (2025) · Anthropology of Consciousness · doi:10.1111/anoc.70010 · Cited by 3
Payne, J., Robinson, O. C., Arnaud, K. O. S., Aday, J. S., Warner, M., Ludlow, C., & Murray, G. (2025) · Brain and Behavior · doi:10.1002/brb3.71043 · Cited by 4
Simon, G., Tadmor, N., & Halperin, D. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105074 · Cited by 3
Sanitizing psychedelics: the biopolitics of non-hallucinogenic psychoplastogens
Hartogsohn, I. (2026) · BioSocieties · doi:10.1057/s41292-025-00377-y · Cited by 4
Bender, D. A., Dunn, H., Pekau, A., Mohite, A. D., Anandarajah, A., Ross, B., Steinle, J. T., Shankar, S., Kiley, B. J., Martin, S., et al. (2026) · BJPsych Open · doi:10.1192/bjo.2025.10974 · Cited by 3
Gold, N. D., Podrebarac, S. K., White, L. A., Marini, C., Simon, N. M., Mittelman, M. S., Ross, S., Bogenschutz, M. P., & Petridis, P. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0011 · Cited by 3
Bender, D. A., & Siegel, J. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00043-9 · Cited by 3
The Paradoxes of Psychedelic Humanities
Langlitz, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-65790-0_15 · Cited by 3
MacLeod, A., Clarke, V., & Warner, C. (2025) · The Arts in Psychotherapy · doi:10.1016/j.aip.2025.102284 · Cited by 3
Clinical Utility of Mystical Experiences: An Overview and Conceptual Framework
Alldredge, C. T., Vagner, M., Corlett, C. E., & Elkins, G. R. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2526351 · Cited by 4
Psilocybin alters visual contextual computations
Aqil, M., de Hollander, G., Vreugdenhil, N., Knapen, T. H. J., & Dumoulin, S. O. (2025) · Nature Communications · doi:10.1038/s41467-025-65150-y · Cited by 3
Acid feminism: Gender, psychonautics and the politics of consciousness
Dymock, A. (2023) · The Sociological Review · doi:10.1177/00380261231175731 · Cited by 3
Mechanisms of integration in psychedelic-assisted therapy
Coverdale, N. S., & Cook, D. J. (2023) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2023-0014 · Cited by 4
Die Rolle der Psychotherapie in klinischen Studien mit Psychedelika
Evens, R., & Wolff, M. (2024) · Die Psychotherapie · doi:10.1007/s00278-024-00715-8 · Cited by 3
Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use
Kruger, D. J., Albrecht, J., Aday, J. S., Barron, J., Herberholz, M., & Boehnke, K. F. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2461999 · Cited by 3
Tunstad, P. A., Kvam, T.-M., Uthaug, M. V., Stewart, L. H., Andersen, K. A. A., & Grønnerød, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1556299 · Cited by 3
Psilocybin: A brief overview for psychiatric mental health nurse practitioners
Fradkin, D. (2021) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12888 · Cited by 3
Carrigan, K., FRANÇOIS, M., Dubus, Z., & Fauvel, B. (2022) · Revue Education Santé Sociétés · doi:10.17184/eac.6033 · Cited by 3
James, E., Robertshaw, T. L., Pascoe, M. J., Chapman, F., Westwell, A. D., & Smith, A. P. (2019) · Drug Science Policy and Law · doi:10.1177/2050324519876123 · Cited by 3
Baseline power of theta oscillations predicts mystical-type experiences induced by DMTPreprint
Tagliazucchi, E., Zamberlán, F., Cavanna, F., de la Fuente, L., Romero, C., Perl, Y. S., & Pallavicini, C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.11.434994 · Cited by 3
Palmer, M., & Maynard, O. (2022) · Research Square · doi:10.21203/rs.3.rs-1457443/v1 · Cited by 4
Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome
Mauney, E. E., King, F., Murray, H. B., & Kuo, B. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002149 · Cited by 3
Psychedelics and schizophrenia: A mystery in history
Haden, M., Woods, B., & Paschall, S. A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00277 · Cited by 6
Psychedelics and cognitive function: A systematic review
Cardoso, C. G., & Viana, M. D. B. (2023) · Research Society and Development · doi:10.33448/rsd-v12i14.44436 · Cited by 2
Becoming a Psychedelic User: Reflections on Howard Becker and the (Future) Sociology of Psychedelics
Rose, J. R. (2025) · Sociology Compass · doi:10.1111/soc4.70096 · Cited by 2
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes
Kishon, R., & Cycowicz, Y. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1637162 · Cited by 3
Dutton, M., Schwenn, P., Mitchell, J., Hoffmann, P., Bailey, N. W., Fitzgerald, P. B., Lagopoulos, J., & Can, A. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251398677 · Cited by 2
How three different theories of depression converge at inflammation
Baumberger, B., Batey, L., & Hashemi, P. (2025) · Discover Mental Health · doi:10.1007/s44192-025-00312-4 · Cited by 2
Realization experiences: a convergent account of insight and mystical experiences
Kim, J. J., Tulver, K., Aru, J., Kaup, K. K., Pogliani, A., & Laukkonen, R. (2026) · Philosophical Psychology · doi:10.1080/09515089.2026.2613030 · Cited by 4
Carlisle, N. A., Simonsson, O., MacCarthy, S., Elliott, M. N., Miller, G. H., Goldberg, S. B., Shallcross, R. A., & Hendricks, P. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-37609-5 · Cited by 4
Advancing the Field of Psychedelic Epidemiology
Simonsson, O., Sun, S., Hendricks, P. S., & Yaden, D. B. (2026) · Psychedelic Medicine · doi:10.1177/28314425261430889 · Cited by 3
Not a Standalone Treatment: Considerations for Psychedelic‐Assisted Therapy
Murphy, S., Stewart, E., Winship, J. R., Kampel, L., Stiel, B., & Ellis, J. (2026) · Brain and Behavior · doi:10.1002/brb3.71280 · Cited by 2
Setting, context and the regulatory atmospheres of psychedelic medicine
Gearin, A. K., Cohen, I. G., & Garcia‐Romeu, A. (2026) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2026.105327 · Cited by 2
Langlitz, N., Greenway, K., Pronovost-Morgan, C., & Gainsley, R. (2026) · Neuroethics · doi:10.1007/s12152-026-09663-3 · Cited by 2
Savoldi, R., Roazzi, A., Escobar, J. A. C., Nour, M. M., & Carhart-Harris, R. L. (2023) · International Journal of Latin American Religions · doi:10.1007/s41603-023-00203-y · Cited by 4
Self-citationChasing the Numinous: Hungry Ghosts in the Shadow of the Psychedelic Renaissance
Osterhold, H. M., & Fernandes‐Osterhold, G. (2023) · Journal of Analytical Psychology · doi:10.1111/1468-5922.12949 · Cited by 4
The Bad Seed: Mystical Experience and Time Travel in the Treatment of Psychopathy
Burton, N. (2023) · Psychoanalytic Dialogues · doi:10.1080/10481885.2023.2264338 · Cited by 2
Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy
Shah, F. I., Shehzadi, S., Akram, F., Haq, I. U., Javed, B., Sabir, S., Kazim, Y., & Ashfaq, S. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00994-7 · Cited by 4
A psilocybin haven: the use of comparison to legitimate transgression at a psychedelic retreat
Dunell, J. (2024) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2024.2412636 · Cited by 2
Ryan, W. C., & Heifets, B. D. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2421895 · Cited by 3
Synthesizing Attachment Theory with the REBUS Model
Cherniak, A. D., Carhart-Harris, R. L., Brulin, J. G., Mikulincer, M., Östlind, S., & Granqvist, P. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.17 · Cited by 2
Self-citationMiller, C. W. T., & Kozak, Z. (2025) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000425 · Cited by 2
Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder
Jones, G. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321461 · Cited by 2
Herbert, M. S., Blanco, B. H., Perivoliotis, D., Luoma, J. B., Fernandes‐Osterhold, G., Bismark, A. W., & Woolley, J. D. (2025) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2025.01.001 · Cited by 3
The Ethics of Set and Setting in Psychedelic Psychotherapy
Patch, K., & Smith, W. (2025) · Neuroethics · doi:10.1007/s12152-025-09600-w · Cited by 2
Emerging From the Dark Side: New Therapeutic Applications of Scheduled Psychoactive Substances
James, E., Robertshaw, T. L., & Westwell, A. D. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0447 · Cited by 2
Whole-brain modeling to predict optimal deep brain stimulation targeting
Fernandes, H. M., Deco, G., & Kringelbach, M. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821861-7.00011-7 · Cited by 2
Psychedelics, embodiment, and intersubjectivity
Blevins, K. R. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00257 · Cited by 2
Early and Contemporary Human Neuroimaging Studies of Serotonergic PsychedelicsPreprint
Tagliazucchi, E. (2020) · Preprints.org · doi:10.20944/preprints202005.0510.v1 · Cited by 1
Ching, T. H. W. (2020) · OpenCommons - UConn (University of Connecticut) · Cited by 2
Ferenstein, G. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3910688 · Cited by 2
Psychology of Religion Approaches to the Study of Religious ExperiencePreprint
Taves, A. (2019) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/pq4yn · Cited by 3
Facilitating real-life creative insight through psychedelic virtual realityPreprint
Siimon, T., Tulver, K., Kaup, K., Vasser, M., & Aru, J. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/zth7f · Cited by 4
Mathai, D. S., Roberts, D. E., Nayak, S. M., Sepeda, N. D., Lehrner, A. L., Johnson, M. W., Lowe, M. X., Jackson, H., & Garcia‐Romeu, A. (2023) · doi:10.31234/osf.io/hm6jn · Cited by 2
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Strika-Bruneau, L., Fauvel, B., Dupuis, D., & Benyamina, A. (2023) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2023.01.003 · Cited by 1
How Psychedelics Can Increase Moral Concern
Dillion, D., Puryear, C., & Gray, K. J. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.22 · Cited by 1
Plourde, L., Chang, S.-L., Farzin, H., Stephan, J.-F., Fallu, J., & Dorval, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00431 · Cited by 2
Arnison, C., Egan, R., & Shaver, J. H. (2025) · Kōtuitui New Zealand Journal of Social Sciences Online · doi:10.1080/1177083x.2025.2467035 · Cited by 1
Exploring the importance of bodyset for the psychedelic experience and beyond
Uthaug, M. V., Allocca, G., Havenith, M. N., Szabó, A., Rosas, F. E., & Ramaekers, J. G. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00418 · Cited by 1
Soto-Angona, Ó., Rodríguez‐Urrutia, A., Ramos‐Quiroga, J. A., Álvarez-Bobo, Ó., Oña, G., Rosal, S. P., París-Pérez, J., & Wolff, M. (2025) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2025.100923 · Cited by 1
Branchi, I. (2025) · Biological Theory · doi:10.1007/s13752-025-00505-8 · Cited by 1
Self-citationSmith, G., Piatkowski, T. M., Ferris, J., Bonenti, B., Davies, E., Barratt, M. J., Morgan, C. J. A., WINSTOCK, A. R., & Puljević, C. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251378509 · Cited by 1
Metadata
- Authors
- Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M.
- Affiliations
- Imperial College London (GB)
- Psychedelic Research Group, Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK
- Istituto Superiore di Sanità (IT)
- Corresponding author
- Carhart-Harris, Robin L
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-02-15
- Volume
- 32
- Issue
- 7
- Pages
- 725-731
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2788854095
- Cited by
- 657
- References
- 62
- Citations by year
- 2026: 83 · 2025: 102 · 2024: 112 · 2023: 105 · 2022: 97 · 2021: 72 · 2020: 49 · 2019: 24 · 2018: 13
- FWCI
- 46.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research (ACF-2013-21-501)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, set and setting, context effects, 5-HT2A receptor agonism, neuroplasticity, long-term mental health outcomes, harm reduction
- MeSH terms
- Animals, Clinical Trials as Topic, Hallucinogens, Humans, Research Design, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
